---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-078295"
form_type: "8-K"
ticker: "SPRY"
cik: "0001671858"
company_name: "ARS Pharmaceuticals, Inc."
filed_at: "2022-03-17T23:59:59+00:00"
generated_at: "2026-06-26T22:02:16.594208+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Silverback Therapeutics Director Thilo Schroeder to not stand for re-election; resigns from audit committee

## Summary
- Dr. Schroeder will not stand for re-election as Class II director at 2022 annual meeting.
- He also resigned from the audit committee effective March 14, 2022.
- Departure is not due to any dispute or disagreement with the company.

## SEC filing metadata
- accession: 0001193125-22-078295
- form_type: 8-K
- ticker: SPRY
- cik: 0001671858
- company_name: ARS Pharmaceuticals, Inc.
- filed_at: 2022-03-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671858/000119312522078295/0001193125-22-078295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671858/000119312522078295/d324895d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-078295
- JSON: https://secwatch.observer/filing/0001193125-22-078295.json
- Plain text: https://secwatch.observer/filing/0001193125-22-078295.txt

## Key facts
- Executive change
  Thilo Schroeder departed as Director at ARS Pharmaceuticals, Inc..
  - Action: not stand for re-election
  - Role: Director
  source text: On March 11, 2022, Thilo Schroeder, Ph.D. informed Silverback Therapeutics, Inc. (the “Company”) that he will not stand for re-election as a member of the Company’s board of directors when his term as a Class II director expires at the Company’s 2022 annual meeting of stockholders and on March 14, 2022, Dr. Schroeder resigned as a member of the audit committee of the board of directors of the Company (the “Audit Committee”) to focus on other endeavors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1671858/000119312522078295/0001193125-22-078295-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.